Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE phase 3 study of relacorilant in endogenous Cushing syndrome
MOH_2019-03-05_005947Phase 3Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of relacorilant in endogenous Cushing's syndrome (3 arms), sponsored by Corcept Therapeutics. Started Feb 2019; status: recruiting.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on MOH_2019-03-05_005947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-05_005947.